🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

9,250 results for “IO” Clear

  1. ATEZOLIZUMAB, COBIMETINIB, VEMURAFENIB

    Fondazione Telethon ETS

    high-risk, surgically resectable BRAF mutated and wild-type Melanoma

    phase 2 small molecule active

    1 trial

  2. ATI 502 0.46% Topical Solution

    Aclaris Therapeutics

    Alopecia Areata

    phase 2 small molecule terminated

    1 trial

  3. ATI-450

    Aclaris Therapeutics

    Cryopyrin-Associated Periodic Syndrome

    phase 2 small molecule terminated

    1 trial

  4. ATI-50002 topical solution

    Aclaris Therapeutics

    Vitiligo

    phase 2 small molecule completed

    1 trial

  5. ATM

    BRIGHT MINDS BIOSCIENCES INC.

    Dual Diagnosis

    phase 2 other completed

    1 trial

  6. AU-011

    Aura Biosciences

    Uveal Melanoma

    phase 2 small molecule completed

    1 trial

  7. AU-011

    Aura Biosciences

    Eye Cancer

    phase 2 small molecule active

    1 trial

  8. AUR200, Isotone Natriumchloridlösung 0,9 % Braun Injektionslösung

    Aurinia Pharmaceuticals

    Generalized Myasthenia Gravis

    phase 2 small molecule active

    1 trial

  9. AUTO1, Cyclophosphamide 500 mg Powder for Solution for Injection or Infusion, Fludara 50 mg powder for solution for injection or infusion

    Autolus GmbH

    Systemic Lupus Erythematosus with Active Lupus Nephritis

    phase 2 small molecule active

    1 trial

  10. AUTO1, MabThera 500 mg concentrate for solution for infusion, AUTO4, MabThera 100 mg concentrate for solution for infusion

    Autolus GmbH

    Potential malignancy in patients who received treatment with Autolus CAR T cell therapy.

    phase 2 small molecule active

    1 trial

  11. AUTOLOGOUS DENDRITIC CELLS LOADED WITH AUTOLOGOUS TUMOR LYSATE, Tecentriq 1 200 mg concentrate for solution for infusion

    The George Institute

    Lung Cancer

    phase 2 small molecule active

    1 trial

  12. AVELUMAB, Erbitux 5 mg/mL solution for infusion

    Fondazione Telethon ETS

    recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  13. AVI-4065 Injection

    Sarepta Therapeutics

    Hepatitis C

    phase 2 small molecule terminated

    1 trial

  14. AVI-4658 for Injection

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  15. AVI-5126

    Sarepta Therapeutics

    Cardiovascular Disease

    phase 2 small molecule terminated

    1 trial

  16. AVTX-801

    Ultragenyx UK Limited

    SLC35A2-CDG - Solute Carrier Family 35 Member A2 Congenital Disorder of Glycosylation

    phase 2 small molecule active

    1 trial

  17. AXATILIMAB, Placebo

    Syndax Pharmaceuticals

    Idiopathic pulmonary fibrosis

    phase 2 small molecule active

    1 trial

  18. AXS-05

    Axsome Therapeutics

    Smoking Cessation

    phase 2 small molecule completed

    1 trial

  19. AXS-05

    Axsome Therapeutics

    Treatment Resistant Depression

    phase 2 small molecule completed

    1 trial

  20. AXS-05 (dextromethorphan-bupropion)

    Axsome Therapeutics

    Treatment Resistant Depression

    phase 2 small molecule terminated

    1 trial

  21. AZD0022, AZD0022, Erbitux 5 mg/mL solution for infusion

    AstraZeneca AB

    Non Small Cell Lung Cancer Colorectal Cancer Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  22. AZD0292

    AstraZeneca

    Bronchiectasis With Pseudomonas Aeruginosa Colonization

    phase 2 mab active

    1 trial

  23. AZD0292, Placebo for AZD0292

    AstraZeneca AB

    Bronchiectasis with chronic pseudomonas aeruginosa colonization

    phase 2 small molecule active

    1 trial

  24. AZD0780, AZD0780, AZD0780 Placebo, AZD0780

    AstraZeneca AB

    Dyslipidemia Dyslipidemias are alterations to the plasma lipid profile associated often with clinical condition. A common form of dyslipidemia is Hypercholesterolemia due to high level of LDL-cholesterol, which is a major risk factor for Cardiovascular Disease (CVD), such as Ischemic Heart Disease and Ischemic Stroke. CVD is a leading cause of global mortality and a contributor to disability.

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources